Twist Bioscience Corporation TWST

Full chart Compare
Set alert

Price alert · TWST

All alert types
121.22 USD -21.36 (-14.98%)

Nov 5, 2026, 2:01 PM EST

118.60 Day range 134.98
25.45 52-week range 205.00
YTD
+282.16%
1 year
+284.58%
Market cap
8.03B
Revenue (ttm)
431.80M
Profit margin
-31.66%
EPS (ttm)
-2.23
Shares out
66.30M
Forward P/E
-356.45
YTD return
+282.16%
1-year return
+284.58%
Volume
1.87M
Avg volume
2.32M
Open
134.79
Previous close
142.58
Day's range
118.60 – 134.98
52-week range
25.45 – 205.00
Beta
2.22
Analysts
Buy
Price target
168.25 (+38.8%)
Earnings date
Nov 12, 2026

2Y +80.08 (+185.63%)

100200Jan 25Jun 25Nov 25Apr 26Aug 26123.22

Key statistics

Enterprise value
8.74B
PEG ratio
0.00
Price / sales
21.89
Price / book
20.05
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
23.20%
Free cash flow
-64.82M
Total cash
166.84M
Total debt
108.59M
Return on equity
-29.59%
Short % of float
19.42%
50-day average
152.76
200-day average
89.95

Financials — quick view

All financials
TWST Revenue — quarterly 118.38M
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026
TWST Net income — quarterly -35.05M
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026
TWST EPS — quarterly -0.56
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026

Earnings

TWST recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2026Sep 30, 2026-0.38452———
Aug 3, 2026Jun 30, 2026-0.50625-0.56-0.05-10.62%
May 4, 2026Mar 31, 2026-0.49-0.71-0.22-44.90%
Feb 2, 2026Dec 31, 2025-0.48-0.50-0.02-4.17%
Nov 14, 2025Sep 30, 2025-0.50-0.45+0.05+10.00%
Aug 4, 2025Jun 30, 2025-0.54-0.47+0.07+12.96%

Upgrades / downgrades

TWST analyst upgrades and downgrades
DateFirmActionFromTo
Oct 13, 2026TD CowenmainBuyBuy
Oct 12, 2026Canaccord GenuitymainBuyBuy
Oct 8, 2026Jefferiesinit—Hold
Oct 7, 2026BarclaysmainOverweightOverweight
Oct 1, 2026GuggenheimmainBuyBuy
Sep 29, 2026Leerink PartnersmainOutperformOutperform

About Twist Bioscience Corporation

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on TWST — it syncs with the Stock Master app.

Insider holders

TWST insider holders
InsiderRelationLatest transactionDateShares held
CHAN NELSON CDirectorStock Award(Grant)Feb 4, 202633,251
CHESS ROBERT BRUCEDirectorSaleAug 6, 202663,612
CHO DENNISOfficerSaleOct 1, 202663,789
CRANDELL KEITH L.DirectorStock Award(Grant)Feb 4, 2026103,618
FINN PATRICK JOHNPresidentSaleOct 22, 2026182,843
GREEN PAULAOfficerSaleOct 1, 2026106,632

Institution ownership

TWST institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.30%5,833,891831.80MJun 29, 2026
Artisan Partners Limited Partnership7.66%4,802,017684.67MJun 29, 2026
FMR, LLC7.50%4,703,044670.56MJun 29, 2026
ARK Investment Management, LLC7.26%4,549,803648.71MJun 29, 2026
Price (T.Rowe) Associates Inc5.80%3,634,652518.23MJun 29, 2026
State Street Corporation5.15%3,232,532460.89MJun 29, 2026

Fund ownership

TWST fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.99%1,874,473267.26MJun 29, 2026
ARK ETF Trust-ARK Innovation ETF2.95%1,847,954263.48MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.73%1,714,174244.41MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.16%1,357,205193.51MJun 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF1.92%1,201,502171.31MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.88%1,177,281167.86MSep 29, 2026